Remove Biosimilars Remove Labelling Remove Process Improvement
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Biosimilars and Complex Generics The rise of biosimilars and complex generics is changing the dynamics of market exclusivity. Staying informed about future trends, such as biosimilars and personalized medicine, is crucial for adapting strategies.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. This step would ensure that real-world considerations, such as off-label uses and quality-of-life impacts, are factored into revised pricing decisions.